

Motif Bio PLC

12:45 15 Apr 2019

Motif Bio still hopeful of reaping the benefit from a productive year

Securing approval in the US for iclaprim remains the top priority for Motif Bio PLC (LON:MTFB), the company said in its full-year results statement.

The company, which is scheduled to meet the US Food and Drug Administration (FDA) in early May to discuss concerns over the risk of liver toxicity for patients taking iclaprim, stressed that securing US approval is but part of a broader plan for iclaprim's long-term success.

READ: Motif Bio receives vote of confidence as it raises £2.7m

"We expect to be joined at the meeting by two external experts and anticipate a collaborative discussion and hopefully an acceptable path forward. We believe that iclaprim can be a valuable option for patients and their providers who are in need of new antibiotic treatment options," said Dr Graham Lumsden, the chief executive officer of Motif.

In the meantime, the company is keeping a tight watch on costs, having posted a sharply reduced loss of US\$14.0m for 2018 compared to a loss of US\$44.8m in 2017.

Research and development expenses decreased to US\$11.0m from US\$29.5m in 2017. This decrease was primarily attributable to a US\$22.1 million reduction in expense for the iclaprim Phase III clinical trial programme, which was completed in 2017, although this was partially offset by a US\$3.6m increase in costs relating to regulatory and clinical operating activities, chemistry manufacturing and control requirements and other non-clinical development activities.

Cash and cash equivalents stood at around US\$12.3m at the end of 2018; since then, the company has raised US\$3.3m through a share issue.

Way forward for iclaprim

As previously mentioned, the company has enough money to get it beyond the meeting with the FDA next month and tide it over while it formulates a plan for the way forward for iclaprim after the meeting.

In a note to clients, analysts at 'house' broker Peel Hunt pointed out: "Our forecasts, recommendation and TP remain U/R and we await the company's perspective following the FDA meeting on 3 May where it will discuss the points raised in the complete response letter (received 14 February) for iclaprim's NDA."

They added: "We note that the company has previously described that - assuming a viable route to approval can be found beyond the FDA meeting - it expects further funds to be required to resubmit an NDA, meet all obligations and reach a new approval date."

In afternoon trading, Motif Bio shares were trading at 8.68p, down 1% on Friday's close.

Price: 0.078

Market Cap: £378.57 k

1 Year Share Price Graph



April 2019 October 2019 April 2020

Share Information

Code: MTFB

Listing: AIM

52 week	High	Low
	11	0.0304

Sector: Pharma & Biotech

Website: www.motifbio.com

Company Synopsis:

Motif Bio is a clinical-stage biopharmaceutical company focused on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant Gram-positive bacteria, including MRSA.

action@proactiveinvestors.com

-- Adds analyst comment, share price --

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.